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Secreting vasoactive factors such as 
adrenomedullin (AM) has been intensively 
investigated due to its vascular protective properties 
and promising potential as a therapeutic target. The 
relationship between adrenomedullin and type (2) 
diabetes needs to be elucidated as it is associated 
with significant elevation in plasma adrenomedullin 
levels. The aim of this study was to evaluate the 
role of adrenomedullin in the development of 
vasculopathy and its significance as a marker 
denoting renal affection in type 2 diabetic patients. 
Materials and Methods: This study was conducted 
on 60 diabetic patients, 20 without nephropathy, 20 
with nephropathy & 20 with diabetic nephropathy 
(DN) on haemodialysis as well as 20 age- and sex-
matched healthy controls. All were subjected to full 
history, Echocardiography, lipid profile analysis 
and plasma adrenomedullin using ELISA method. 
Results: plasma AM concentration was elevated in 
all groups of diabetic patients and increment was 
dependent on the severity of DN (P<0.0001, 
P<0.0001), P<0.0001 respectively). There were 
positive correlation between adrenomedullin and 
left ventricular internal dimensions both in diastole 
& systole (P<0.001, P<0.005) and negative 
correlation between AM and ejection fraction (EF) 
P<0.0001. There was positive correlation between  
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adrenomedullin and cholesterol, triglycerides and 
LDL (p<0.002, p<0.001and p<0.003 respectively) 
and a negative correlation with HDL (P<0.004). 
Conclusion: Adrenomedullin is supposed to play a 
role in the pathogenesis of diabetic 
microvasculopathy in renal patients. So it can be 
used to identify high-risk subjects and modulating 
its action would have therapeutic potential in the 
prevention of diabetic nephropathy.  
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Type 2 diabetes mellitus contributes greatly to 
morbidity, mortality, and over all health care cost. 
These outcomes are derived from the high 
incidence of progressive kidney dysfunction, 
making diabetic nephropathy the leading cause of 
end stage renal disease [1]. For a lesser extent from 
the atherogenic dyslipidemia which typically 
presents in type 2 diabetic patients [2]. 
Hemodynamic-mediated
 
vascular injury was 
identified as one mechanism in the pathogenesis of 
diabetic nephropathy. Sustained increase in 
glomerular capillary
 
pressure driven by increase in 
plasma flow had been observed,
 
especially in early 
stages of nephropathy. The elevation in
 
glomerular 
capillary pressure might be damaging to glomerular
 
endothelial, epithelial, and mesangial cells, thereby 
 initiating
 
and contributing to the progression of 
nephropathy. Although
 
numerous mediators of 
diabetic hyperfiltration had been proposed,
 
the 
exact mechanism remained unclear [3]. It is 
therefore tempting
 




adrenomedullin could be involved, since plasma 
midregional proadrenomedullin (MR-proADM) 
was increasingly
 
elevated from healthy to renal-
impaired subjects and
 
well correlated to magnitude 
of microcirculatory perfusion. Should this be the 
case, modulating adrenomedullin action would
 
have 




In healthy states, adrenomedullin circulates at low 
picomolar
 
concentration, which increases 
significantly in a number of
 
disease states including 
congestive heart failure, sepsis, essential
 




increased vascular adrenomedullin expression [5]. 
Some investigators reported that type 2 diabetes 
was associated with significant elevation of plasma 
adrenomedullin [6], whereas others suggested that 
increment in plasma adrenomedullin was dependant 
on the severity of diabetic nephropathy [7].  
Adrenomedullin is produced by several 
cardiovascular tissues including the myocardium, 
vascular endothelium and vascular smooth muscle 
[8], exerting vasodilator, natriuretic, diuretic, 
angiogenic, anti-fibrotic and anti-oxidant actions 
[9]. Although an endocrine and neurocrine function 
in the physiological regulation of water intake has 
been identified [10], attention has focused upon 
autocrine/ paracrine actions of AM within the 
myocardium, notably during and following 
ischemia. 
Several studies have demonstrated that AM exerts a 
potent cardio protective action against ischemia-
reperfusion injury, and reduced left ventricular 
remodeling and fibrosis [11]. 
 
Aim of the work: To evaluate the role of 
adrenomedullin in the development of vasculopathy 
and its significance as a marker denoting renal 
affection in type 2 diabetic patients. 
 
Material and methods 
 
This study was conducted on 60 patients selected 
from Nephrology Department of Theodore Bilharz 
Research Institute (TBRI) and 20 controls 
categorized into 4 groups:  
 Group 1 included 20 healthy age- and sex-
matched healthy controls (12 males and 8 
females with mean age of 56.05±6.3) 
volunteered from the medical and paramedical 
staff. 
 Group 2 included 20 type 2 diabetic patients 
(12 males and 8 females with mean age 
58.05±7.6).The patients were diabetic without 
nephropathy as evidenced by absence of 
microalbuminuria in collected urine over 24hs. 
 Group 3 included 20 type 2 diabetic patients 
(10 males and 10 females with mean age 
59.15±6.6). The patients were diabetic with 
nephropathy as evidenced by presence of 
macroalbuminuria in collected urine over 24 
hrs.  
 Group 4 included 20 type 2 diabetic patients 
(11males and 9 females with mean age 
55.95±4.5). The patients were diabetic 
nephropathy with chronic renal failure (CRF) 
selected from the Hemodialysis Unit and were 
on regular hemodialysis sessions 3 times 
weekly, 4 hours each.   
 
Both patients and controls have no history of 
myocardial infarction, cardiomegaly, heart failure, 
or any known history of chronic medical
 
illness. 
We excluded patients with hematuria, renal 
insufficiency of unexplained
 
origin, urinary tract 
infection, and history of rapidly progressive
 
renal 
failure, glomerulonephritis, and polycystic kidney 
diseases. 
All subjects underwent routine clinical examination 
and Laboratory Investigations including: 
Blood sugar, blood urea, serum creatinine, 
creatinine clearance, serum cholesterol, 
triglycerides, (HDL-C), and (LDL-C). The 
laboratory investigations were done to all subjects 
after an overnight fasting, (just before initiation of 
dialysis in HD patients).  
A new immunoluminometric assay targeted
 
at 
midregional proadrenomedullin [MR-proADM] 
was performed using a novel
 
sandwich 
immunoassay (B.R.A.H.M.S. Sevadil LIA; 
B.R.A.H.M.S.,
 
AG, Hennigsdorf/Berlin, Germany) 
[12]. The assay has an analytical detection limit of 
0.08 nmol/l,
 
and the interassay CV is <20% for 
values >0.12 nmol/l. EDTA, heparin, and citrate 
plasma samples are stable
 
(<20% loss of analyte) 
for at least 3 days at room temperature,
 
14 days at 
4°C, and 1 year at –20°C. 
12 lead Electrocardiogram ECG and Transthoracic 
Echocardiography (TTE) were done to all patients 
and the control group by Toshiba nemio system, 
using 2.5 MHZ phased array transducer. Each TEE 
study included M-mode, two dimensional 
echocardiography, Doppler and color flow 
mapping. 
 All patients gave informed consent and the study 





Data were statistically described in terms of mean  
standard deviation ( SD). Comparison of more 
than 2 variables was done by ANOVA test.  
Pearson correlation between various variables was 
evaluated and significant correlation was presented 
by graphs. A probability value (p value) less than 
0.05 was considered statistically significant. All 
statistical calculations were done using computer 
programs Microsoft Excel version 7(Microsoft 
Corporation, NY, USA) and SPSS (Statistical 
Package for the Social Science; SPSS Inc., 




The demographic data of patients and controls were 
listed in table (1). 
Table (2) shows the laboratory data of different 
groups of patients and controls. There was a highly 
significant increase in total cholesterol, 
triglycerides and LDL in between the different 
groups of patients and (p<0.0001, p<0.0001, 
p<0.0001) and there was a highly significant 
decrease in HDL between the control and all groups 
of patients (P<0.0001, P<0.0001, P<0.003). There 
was a highly significant increase in urea and 
creatinine between the control and all different 
groups of patients (P<0.001, P<0.0001P<0.0001). 
There was a highly significant decrease in 
creatinine clearance between the control and all 
different groups of patients (P<0.0001, P<0.0001, 
P<0.0001). There was a highly significant increase 
in HA1c between the control and all different 
groups of patients (P<0.001, P<0.006 P<0.0001). 
Blood pressure was significantly increased in all 
patients compared to the control group (P<0.001, 
P<0.001, P<0.001). 
Plasma adrenomedullin was significantly increased 
in all patients compared to the control group 
(P<0.0001, P<0.0001, P<0.0001). 
Echocardiograpgy of patients and control were 
listed in table (3); There was a significant increase 
in left ventricular internal dimensions both in 
diastole and in systole (LVIDd & LVIDs) between 
the control and all patients groups. There was a 
significant decrease in ejection fraction (EF %) 
between the control and all patients groups 
(P<0.0001, P<0.0001, P<0.005).There was also a  
significant increase in left ventricular mass index 
(LVMI) between the control and all groups 
(P<0.0001, P<0.0001, P<0.0001). 
Table (4): shows the correlation between 
adrenomedullin and laboratory parameters, there 
was positive correlation between adrenomedullin 
and left ventricular internal dimensions both in 
diastole & systole (P<0.001, P<0.005) and negative 
correlation between AM and ejection fraction (EF) 
P<0.0001. There was positive correlation between 
adrenomedullin and cholesterol, triglycerides and 
LDL (p<0.002, p<0.001and p<0.003 respectively) 
and a negative correlation with HDL (P<0.004). 
 




































M 12 (60%) 
F 8 (40%) 
 
M 12 (60%) 
F 8 (40%) 
 
M 10 (50%)  
F 10 (50) 
 
M 11 (55%) 
















































120.00±5.68 135.20±8.48 141.40±7.0 152.00±6.92   




76.00±3.50 84.00±5.20 86.80±6.44 96.20±6.96    
























22.4±2.1 25.6±3.2 90±24.4 131.7±25.2 .001 .0001 .0001 



















6.4±2.1 9.6±1.2 8.2 ±0.5 .0001 0.006 0.0001 
AM  
nmol/l 
1.1±0.6 8.4±3.8 10.3±6.8 33±39.6 .0001 .0001 .0001 
 
SBP: systolic blood pressure, DBP: diastolic blood pressure 
BU: blood urea, SCr: serum creatinine, Cr Cl: creatinine clearance 
HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol  
AM: adrenomedullin 
 











































2.9±0.6 2.98±0.35 3.6±0.53 4.0±07 Ns .0001 .051 
EF (%) 
  




79.3±16.1 128.2±19.5 184.6±19.6 215.8±32.6 .0001 .0001 .0001 
 
LVIDd: left ventricular internal dimension (diastole), LVIDs: left ventricular internal dimension (systole), EF: ejection fraction, LVMI: left 
ventricular mass index 
  













Cr clearance -0.48 0.002 
LVIDd 0.54 0.001 
LVIDs 0.44 0.005 
EF -0.63 0.0001 
LVMI 0.52 0.001 
Cholesterol 0.48 0.002 
Triglycerides 0.52 0.001 







In our study it was found that, plasma AM
 
concentration was elevated in all diabetic patients 
with and without nephropathy and increment in 
plasma adrenomedullin was dependent on the 
severity of diabetic nephropathy (p<0.0001, 
p<0.001, p<0.001 respectively), this was consistent 
with findings of others [11,13 &14]. 
We found also a positive correlation between AM 
and creatinine (r=0.59, p<0.0001) and a negative 
correlation between AM and creatinine clearance 
(r=-0.48& P<0.002). 
Few studies have investigated the relationship 
between adrenomedullin and type 1 diabetes [15], 
however other studies showed that type 2 diabetes 
was associated with significant elevation in plasma 
adrenomedullin levels, [16].  
Previous elegant studies
 
suggested kidney as an 
important source of adrenomedullin, [17], whereas 
pulmonary vascular bed could be the main site of 
receptor-dependent
 
clearance of circulating 
adrenomedullin [18].  In contrast, the
 
exact site of 
clearance for MR-proADM is not known at the 
moment.
 




among type 2 diabetes with nephropathy
 
could be 
reduced MR-proADM clearance [19].  
It is known that adrenomedullin
 
could exert a wide 
range of vascular actions (mostly protective).
 
These 
include endothelium-dependent and -independent 
vasodilatation,
 




of vascular smooth muscle cell,
 
and adventitial 
fibroblast [19]Taken together, the elevation
 
of 
plasma MR-proADM concentration in type 2 
diabetes (especially
 
in the presence of nephropathy) 
could be an appropriate physiological
 
response to 
ongoing vascular injury [20] . 






that hyperglycemia might increase vascular 
adrenomedullin
 
expression [21]. Other postulated 
mechanisms included acute hyperinsulinemia, [22], 
increased oxidative stress (based on in vivo studies)
 
[23], and proatherogenic/inflammatory factors such 
as angiotensin
 
II and endothelin-1 [24]. 
Plasma AM levels were increased in patients with 
renal impairment in proportion to the severity of the 
disease. AM was related
 
to multiple metabolic 
factors and basal microcirculatory perfusion.
 
Therefore, adrenomedullin might play a role in the 
pathogenesis
 
of diabetic vasculopathy [25]. 
Iemura et al [26] investigated the levels of 
adrenomedullin AM during
 
the process of 
preadipocyte differentiation and its role in
 
lipid 
metabolism and cellular signaling mechanism in 
differentiated
 
adipocytes. They found that AM and 
its receptor component were highly expressed in 
cultured
 
adipocytes and may play a role in lipid 
metabolism via a different
 
signaling pathway.   
Our study revealed that there were a highly 
significant hyperlipidemia in different groups of 
patients and controls (P <0.0001, P <0.0001, P 
<0.0001) and the atherogenesis process is much 
more aggravated in diabetic uremic patients. These 
 findings were in agreement with others, who 
reported that hyperlipidemia is involved in the 
progression of diabetic nephropathy through 
playing a pathological role in progressive 
glomerular injury [27]. 
In agreement with the previous findings, Bodlaj et 
al [28], stated that hyperlipidemia in hemodialysis 
dependent diabetic patients can mediate the 
inflammation of vessel walls in levels exceeding 
those hemodialysis dependent patients without 
diabetes mellitus. 
We found also a positive correlation between 
adrenomedullin and Cholesterol, trigylecerides and 
LDL (r=0.47& P<0.002, r=0.52 & P<0.001 and 
r=0.47 & P<0.003 respectively) and negative 
correlation between AM and HDL (r=-0.46& 
P<0.004). The relationship between LDL 
cholesterol and adrenomedullin is poorly 
understood. Limited in vitro data from endothelial 
cells in rats suggested that oxidized LDL might 
stimulate the secretion of adrenomedullin [28], 
which was in agreement with our result. 
Other studies, however, could not document any 
relationship between plasma adrenomedullin 
concentrations and the degree of metabolic control 
or risk factors traditionally associated with 
endothelial injury (e.g., hypertension and 
dyslipidemia), [6,29]. 
Levy et al and Burley et al [30,31] stated that AM 
exerts Ca (2+)-dependent positive inotropic effects 
in human atrial and less-pronounced effects in 
ventricular myocardium. The inotropic effects were 
related to increased cAMP levels. 
In our study we found a significant increase in 
LVIDd, LVIDs and LVMI with significant 
reduction in EF in group 4 when compared with 
group 3 patients and the latter group of patients 
more than group2, who were in turn more than the 
control group. This means that the worse the degree 
of the renal insult due to diabetes, the more increase 
in LV dimensions and LVMI. This result may be 
due to hyperglycemia with or without insulin 
resistance, especially in the presence of diabetic 
nephropathy. Our findings was in agreement with 
others [32], who stated that the increased arterial 
stiffness can contribute to increase in LVM by 
elevating cardiac after load, where the increase  in 
LVM could be viewed as an adaptive response to 
keep left ventricular wall stress constant and 
preserve left ventricular systolic function. Henry et 
al [33] attributed also these findings to other factors 
such as increased oxidative stress, presence of 
chronic low grade inflammation and the presence of 
autonomic neuropathy. 
In our study adrenomedullin was positively 
correlated with LVIDd, LVIDs & LVMI, (r=0.54 & 
P<0.001, r=0.44 & P<0.005 and r=0.52 & P<0.001 
respectively) and negatively correlated with EF (r=-
0.63 & P<0.001). 
Several studies have demonstrated that AM exerts a 
potent cardio protective action against ischemia-
reperfusion injury, and reduced left ventricular 
remodeling and fibrosis [9], while others found that  
mesenchymal stem cells transplantation can inhibit 
function of cardiac fibroblasts by secreting 
antifibrotic factors such as AM, resulting in 
decrease myocardial fibrosis [34]. 
Plasma MR-proADM levels increase in association 
with cardiac dysfunction, systemic inflammatory 
status and systemic blood volume in haemodialysis 
patients with concomitant cardiovascular disease 
[16]. These finding were in agreements with our 
findings. 
In conclusion, our study revealed that plasma AM 
concentration
 
was elevated among subjects with 
type 2 diabetes, which was
 
further accentuated 
when nephropathy set in. AM was related
 
to 
multiple metabolic factors and basal micro-
circulatory perfusion. Therefore, adrenomedullin 
might play a role in the pathogenesis
 
of diabetic 
vasculopathy. Modulating adrenomedullin action 
would have therapeutic potential in the prevention 
of diabetic nephropathy. 
 
DISCLOSURE OF CONFLICT OF INTEREST: 





1. Vallon V, Blantz R, and Thomson S.:  Glomerular 
hyperfilteration and the salt paradox in earely type 1 
diabetes mellitus: a tubulocentric view.  J Am Soc 
Nephrol 2003; 14: 530-537. 
2. Tenenbaum A, Fisman E, Motro M, and Adler Y.: 
Atherogenic dyslipidemia in metabolic syndrome and type 
2 diabetes: therapeutic options beyond statins. 
Cardiovascular Diabetology 2006: 5- 20.  
3. O'Donnell MP, Kasiske BL, Keane WF.:  Glomerular 
hemodynamic and structural alterations in experimental 
diabetes mellitus. FASEB J 1998; 2:2339–2347. 
4. Julian M, Cacho M, Garcia MA et al.: Adrenomedullin: a 
new target for the design of small molecule modulators 
with promising pharmacological activities. Eur J Med 
Chem 2005; 40:737–750. 
5. Cao YN, Kitamura K, Kato J, Kuwasako K, Ito K, 
Onitsuka H.:  Chronic salt loading upregulates expression 
of adrenomedullin and its receptors in adrenal glands and 
kidneys of the rat. Hypertension 2003; 42:369–372. 
6. Turk HM, Buyukberber S, Sevinc A et al.: Relationship 
between plasma adrenomedullin levels and metabolic 
control, risk factors, and diabetic microangiopathy in 
patients with type 2 diabetes. Diabetes Care 2000; 
23:864–867. 
7. Nakamura T, Honda K, Ishikawa S, Kitamura K, Eto T 
and Saito T.: Plasma adrenomedullin levels in patients 
 with non-insulin dependent diabetes mellitus: close 
relationships with diabetic complications. Endocr J 1998; 
45:241–246. 
8. Widlansky ME, Gokce N, Keaney JF, Vita JA.: The 
clinical implications of endothelial dysfunction. J Am 
Coll Cardiol 2003; 42:1149–60. 
9. Okumura H, Nagaya N, Kangawa K.: Adrenomedullin 
infusion during ischemia/reperfusion attenuates left 
ventricular remodeling and myocardial fibrosis in rats. 
Hypertens Res 2003; 26:99–104. 
10. Beltowski J, Jamroz A.: Adrenomedullin-what do we 
know 10 years since its discovery?  Pol J Pharmacol 2004; 
56:5–27 
11. Charles CJ, Rademaker MT, Richards AM, Cooper GJ, 
Coy DH, Nicholls MG.: Hemodynamic, hormonal, and 
renal effects of intracerebroventricular adrenomedullin in 
conscious sheep. Endocrinology 1998; 139:1746–1751 
12. 12- Morgenthaler NG, Struck J, Alonso C, Bergmann A.: 
Measurement of midregional proadrenomedullin in 
plasma with an immunoluminometric assay. Clin Chem   
2005; 51:1823–1829.  
13. Kinoshita H, Fujimoto S, Tokura T, Hisanaga S, Kitamura 
K, Eto T.: Plasma mature form of adrenomedullin in 
diabetic nephropathy. Intern Med 2001; 40:841–2. 
14. Lim SC, Morgenthaler NG, Subram AT et al.: The 
relationship between adrenomedullin, metabolic factors, 
and vascular function in individuals with type 2 diabetes. 
Diabetes Care 2007; 30:1513-9. 
15. Garcia-Unzueta MT, Montalban C, Pesquera C, 
Berrazueta JR, Amado JA.: Plasma adrenomedullin levels 
in type 1 diabetes: relationship with clinical parameters. 
Diabetes Care 1998; 21:999–1003. 
16. Yoshihara F, Ernst A, Morgenthaler NG et al. 
Midregional proadrenomedullin reflects cardiac 
dysfunction in hemodialysis  patients  with cardiovascular 
disease. Nephrol Dial Tranplant 2007; 22:2263-8. 
17. Eto T, Kitamura K, Kato J.: Biological and clinical roles 
of adrenomedullin in circulation control and 
cardiovascular diseases. Clin Exp Pharmacol Physiol 
1999; 26:371–380. 
18. Nishikimi T, Kitamura K, Saito Yet al.: Clinical studies 
on the sites of production and clearance of circulating 
adrenomedullin in human subjects.Hypertesion1994; 
24:600-604. 
19. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T.: 
Adrenomedullin: a protective factor for blood vessels. 
Arterioscler Thromb Vasc Biol 2005; 25:2480–2487.  
20. Ishimitsu T, Nishikimi T, Saito Y et al.: Plasma levels of 
adrenomedullin, a newly identified hypotensive peptide, 
in patients with hypertension and renal failure. J Clin 
Invest 1994; 94:2158–2161. 
21. Hayashi M, Shimosawa T, Fujita T.: Hyperglycemia 
increases vascular adrenomedullin expression. Biochem 
Biophys Res Commun 1999; 258:453–456. 
22. Katsuki A, Sumida Y, Gabazza EC et al.: Acute 
hyperinsulinemia is associated with increased circulating 
levels of adrenomedullin in patients with type 2 diabetes 
mellitus. Eur J Endocrinol 2002; 14:71–75.  
23. Katsuki A, Sumida Y, Urakawa H et al.: Increased 
oxidative stress is associated with elevated plasma levels 
of adrenomedullin in hypertensive patients with type 2 
diabetes. Diabetes Care 2003; 26:1642–1643. 
24. Sugo S, Minamino N, Shoji H, Kangawa K, Matsuo H.: 
Effects of vasoactive substances and cAMP related 
compounds on adrenomedullin production in cultured 
vascular smooth muscle cells. FEBS 1995; 369:311–314. 
25. Sjoholm A, Nystrom T.: Endothelial inflammation in 
insulin resistance. Lancet 2005; 365:610–615. 
26. Iemura-Inaba C, Toshio Nishikimi T, Akimoto K, 
Yoshihara F, Minamino N and Matsuoka H.:  Role of 
adrenomedullin system in lipid metabolism and its 
signaling mechanism in cultured adipocytes Am J Physiol 
Regul Integr Comp 2008; 295: 1376-1384. 
27. Prichard S.: Impact of dyslipidemia in end stage renal 
disease. Am Soc Nephrol 2003; 14: 315- 320. 
28. Bodlaj G, Berg J, Pichler R, Sailer T, and Biesenbach G.: 
Type 2 diabetes in patients with end stage renal disease is 
not associated with further increased serum inflammatory 
parameters. J. Nephrol 2004; 17: 112-117. 
29. Kinoshita H, Kato K, Kuroki M et al.: Plasma 
adrenomedullin levels in patients with diabetes. Diabetes 
Care 2000; 23:253–254. 
30. Levy D, Hwang SJ, Kayalar A et al.: Association of 
plasma natriuretic peptide, adrenomedullin and 
homocysteine levels with alterations in arterial stiffness: 
the Framingham Heart Study. Circulation 2007; 115:307-
85. 
31. Burley DS, Hamid SA and Baxter G F.: Cardioprotective 
actions of peptide hormones in myocardial ischemia. 
Heart fails Rev 2007; 12:279-91. 
32. Lakatta E. and Levy D.: Arterial and cardiac aging: major 
shareholders in 9 cardiovascular disease enterprises. Part 
II: the aging heart in health: links to heart disease. 
Circulation 2003; 107: 346- 354. 
33. Henry R, Otto K, Kostense P et al.: Left ventricular mass 
increases with deteriorating glucose tolerance, especially 
in women: Independence of increased arterial stiffness or 
decreased flow mediated dilation. Diabetes Care 2004; 27: 
522- 529. 
34. Li L, Zhang S, Zhang Y, Yu B, Guan Z.: Paracrine actions 
mediate the antifibrotic effect of transplanted 
mesenchymal stem cells in a rat model of global heart 
failure. Mol Biol Rep 2008; 27: 1355–1363.  
 
 
